Loan & DebtAug 11, 2026, 07:06 AM
BioXcel Therapeutics Extends Debt Repayment Deadline, Lowers Liquidity
AI Summary
BioXcel Therapeutics, Inc. entered into the Twelfth Amendment to its Credit Agreement, extending the deadline for securing definitive agreements for debt repayment or alternative capital solutions to August 21, 2026. This amendment also reduced the minimum liquidity covenant from $6.25 million to $3.0 million. The required transactions must be acceptable to the company's lenders.
Key Highlights
- BioXcel Therapeutics entered into the Twelfth Amendment to its Credit Agreement on August 10, 2026.
- Deadline for securing definitive agreements for debt repayment or alternative capital solutions extended to August 21, 2026.
- The previous deadline for these agreements was August 10, 2026.
- Minimum liquidity covenant reduced from $6.25 million to $3.0 million.
- All transactions for repayment or capital solutions must be acceptable to the lenders.
Price Impact
More from BTAI